SENZAGEN AB revenue for the last year amounted to 4.47 M EUR, the most of which — 4.46 M EUR — came from its highest performing source at the moment, Genomic Allergen Rapid Detection, the year earlier bringing 3.73 M EUR. The greatest contribution to the revenue figure was made by Sweden — last year it brought SENZAGEN AB 4.46 M EUR, and the year before that — 3.73 M EUR.